MoneyWorks4Me

Lupin’s arm receives USFDA approval for Generic Plan B Tablets

24 Jan 2013 Evaluate

Pharma major, Lupin’s subsidiary - Lupin Pharmaceuticals Inc (collectively Lupin) has received final approval for its Levonorgestrel Tablets USP, 0.75 mg (Rx/OTC) from the United States Food and Drugs Administration (US FDA) to market a generic version of Teva Branded Pharmaceutical Products R&D, Inc.’s Plan B Tablets, 0.75 mg.

Lupin’s Levonorgestrel Tablets Levonorgestrel 0.75mg tablets is a progestin?only emergency contraceptive, indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure.

Plan B Tablets had annual US sales of approximately $81.1 million (IMS MAT Sept 2012 sales).

Lupin Share Price

2111.00 -24.00 (-1.12%)
04-Sep-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1899.00
Dr. Reddys Labs. 1154.00
Cipla 1385.00
Lupin 2111.00
Zydus Lifesciences 1121.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: